New hope for rare bone disease pain?
NCT ID NCT01791842
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tested a drug called tocilizumab for people with fibrous dysplasia of bone who still had pain after standard treatment. The drug blocks a protein linked to bone damage. Nineteen adults took part in this small, early-stage trial to see if the drug could reduce bone pain and markers of bone breakdown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Rhumatologie, Groupe Hospitalier Pellegrin
Bordeaux, France
-
Service de rhumatologie, Hopital Edouard Herriot, HCL
Lyon, 69003, France
-
Service de rhumatologie, Hôpital Lariboisière
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.